OrthoPediatrics Corp. has spent the past month quietly rerating, with the stock up nearly 20% to $19.95 and short sellers trimming positions — yet the analyst community has barely moved since earnings, leaving a gap between the recovery in the share price and the conviction on the Street.
The most striking feature of the short data is the direction of travel, not the level. Short interest has fallen roughly 12% over the past month to 3.4% of free float — a modest absolute position that was already never the dominant story here, but the steady unwind through June adds texture to the price recovery. Borrowing costs remain low at 0.71%, well below any level that would signal stress in the lending market. Availability is generous at 774%, meaning there are roughly eight shares available to borrow for every one currently lent out — far from the tightest point of the past year at 393%. Options carry no signal at all: the put/call ratio has been zero for weeks, reflecting the thinly traded nature of the name. Together, the lending and options picture says this stock is not a battleground — it is recovering quietly.
The Street backdrop is constructive but has grown stale. The most recent analyst action on record is a May 2026 reiteration from BTIG at a $24 Buy, with no new moves since. The consensus mean target of $24.67 sits about 24% above the current price, which is plausible given the name's trajectory, though most of the target-setting happened between October 2025 and February 2026. The bull case centres on margin expansion — 50 basis points of gross margin improvement, 280 basis points of adjusted EBITDA margin growth — and Trauma & Deformity sales running above estimates at $44.1 million and up 17%. The bear case is simpler: revenue growth has decelerated from 15.7% to 12.2%, deployed sets fell from $5.3 million to $4.1 million year-over-year, and sales rep attrition remains a live operational headwind. The forward EPS improvement factor ranks in the 88th percentile — a bright spot — but quality metrics are weak, with a low Piotroski score, negative ROA, and thin free cash flow. The ORTEX short score of 46, running slightly below its mid-June levels near 48-49, places the stock in neutral territory rather than suggesting any acute pressure.
Institutional ownership tells the more interesting story at this level. Squadron Capital holds a dominant 26.9% stake — its position unchanged in the most recent filing — making the stock highly sensitive to the views of a single concentrated holder. Granahan Investment Management added 232,760 shares in the most recent period, a meaningful move for a name with this level of liquidity. BlackRock added 33,705 shares through June 30. On the other side, Wellington trimmed 132,252 shares. The insider data is now slightly dated — the most recent transactions were a cluster of executive sales in mid-March at $17.25, all tagged with low significance scores and coming shortly after a round of stock awards, suggesting routine plan activity rather than a directional read. CEO David Bailey's current 1.6% holding and the concurrent awards-then-sales pattern support that read.
Earnings history adds a relevant frame. The last two prints produced outsized reactions: plus 9% the day after May 2026 results and plus 6.8% after April's report, with the five-day follow-through reaching 10% and 20% respectively. The next event is set for August 3. Whether the stock's 20% monthly run reflects investors pre-positioning for another beat, or simply the absence of sellers, is the central question heading into that print.
See the live data behind this article on ORTEX.
Open KIDS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
